Abstract: Disclosed herein is a modified transposase, comprising a core piggy Bac transposase having one or more modifications making it capable of excising and integrating a piggy Bac transposon in LE/LE configuration leading to hyperactivity. Also disclosed is a modified piggy Bac transposase capable of excising but not integrating a piggy Bac transposon in LE/LE configuration. Also disclosed herein is a modification of the mammalian Myotis lucifugus DNA transposon involving modification both its transposase and transposon LE and RE ends by truncations leading to hyperactivity.

Abstract: Disclosed herein are engineered cell-based peptide delivery platforms based on T cells lacking Perforin function. Perforin-null T cells lack cytotoxic effector function and thus are not capable of killing target cells by conventional Perforin dependent pathways. However, they efficiently home to target tissues where they can invade, persist, and proliferate. The homing ability of perforin lacking T cells can therefore be used to deliver anti-cancer or pre-immune peptides to tumors, or therapeutic peptides to other target tissues based on antigen recognition. Because the cells lack cytotoxic effector function due to loss, knockdown, or inhibition of Perforin, they can be targeted to tissues based on antigen recognition without destroying the target tissue directly.

Abstract: Disclosed herein are compositions comprising integrating enzymes that can deliver nucleic acids to a target DNA. Additionally, the methods of using the compositions disclosed herein relate to treatments for a variety of infections, conditions, and genetic disorders.